DRIVE REAL Study

• Research type

  Research Study

• Full title

  Real World Utilisation of Doravirine

• IRAS ID

  291575

• Contact name

  Ana Milinkovic

• Contact email

  Ana.Milinkovic@chelwest.nhs.uk

• Clinicaltrials.gov Identifier

  N/A, N/A

• Duration of Study in the UK

  0 years, 2 months, 31 days

• Research summary

  There is a lack of published real world data on the use of doravirine (DOR), and these data will show how DOR is used in the real world setting in the UK. This study will provide data on patient characteristics and treatment patterns of HIV positive patients starting DOR. The study will be carried out in 3 NHS hospital HIV departments in the UK. We will aim to recruit up to 300 HIV-1 positive patients from these 3 NHS sites. Patients that will be part of the study will be those with a HIV-1 infection and treated with DOR. However, the study will only collect historic data from the patient medical records by the healthcare team. Patients themselves do not need to do anything, there will be no changes to their care and they will not undergo any procedures as part of the research. Doctors (or their research teams) that have treated the patients identified for this study will fill out a form online in order to provide anonymised information about the patient’s treatment history. Data collection will last a few months to
  provide enough time to extract the data. The study is sponsored and funded by Merck Sharp & Dohme (UK) Ltd

• REC name

  Yorkshire & The Humber - South Yorkshire Research Ethics Committee

• REC reference

  21/YH/0062

• Date of REC Opinion

  11 Mar 2021

• REC opinion

  Favourable Opinion